William Blair Starts Inari Medical Inc. (NARI) at Outperform

William Blair analyst Margaret Andrew initiates coverage on Inari Medical Inc. (NASDAQ: NARI) with a Outperform rating.

The analyst comments "Large Underpenetrated Markets With Upcoming Clinical Data Catalysts: Inari has three pivotal trials in progress, with the first (PEERLESS) expected to read out in the next few months, and a fourth in high-risk pulmonary embolism (PE) likely to be announced soon. Results to date from large-scale registries have shown the clinical benefit of Inari’s ClotTriever and FlowTriever devices. Positive results from upcom-ing RCTs could accelerate adoption in the venous markets Inari operates in today."

For an analyst ratings summary and ratings history on Inari Medical Inc. click here. For more ratings news on Inari Medical Inc. click here.

Shares of Inari Medical Inc. closed at $55.39 yesterday.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
• JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral